Metis TechBio in deal for experimental autoimmune drug worth up to $1.6 billion

Metis TechBio granted U.S. biotech Boulevard Bio exclusive global rights to develop, manufacture, and commercialize experimental autoimmune drug MTS-128. The licensing deal is potentially worth up to $1.6B, signaling a positive commercial validation of the program, though the immediate financial impact is likely limited until milestones are triggered.

Analysis

Metis TechBio granted U.S. biotech Boulevard Bio exclusive global rights to develop, manufacture, and commercialize experimental autoimmune drug MTS-128. The licensing deal is potentially worth up to $1.6B, signaling a positive commercial validation of the program, though the immediate financial impact is likely limited until milestones are triggered.